Clinical comprehensive evaluation of five marketed thrombopoietin receptor agonists in China
- VernacularTitle:我国5种上市血小板生成素受体激动剂的临床综合评价
- Author:
Yunjin ZHANG
1
;
Xiaorong WU
1
;
Zhiyun HUANG
2
;
Meiyan ZHANG
2
;
Fan ZHANG
2
;
Hongtao LIU
2
Author Information
1. Graduate School，Hebei Medical University，Shijiazhuang 050017，China
2. Dept. of Pharmacy，the First Hospital of Hebei Medical University，Shijiazhuang 050032，China
- Publication Type:Journal Article
- Keywords:
thrombopoietin receptor agonists;
Eltrombopag olamine tablets;
Lusutrombopag tablets;
drug selection
- From:
China Pharmacy
2026;37(2):142-148
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To conduct a clinical comprehensive evaluation of five marketed thrombopoietin receptor agonists （TPO-RA） approved in China， providing quantitative evidence for drug selection and therapeutic decision-making in medical institutions. METHODS Relevant data on Romiplostim for injection， Eltrombopag olamine tablets， Herombopag olamine tablets， Avatrombopag maleate tablets， and Lusutrombopag tablets were collected. Based on the Chinese Rapid Guide for Drug Evaluation and Selection in Medical Institutions （Second Edition）， 12 formulations of these five TPO-RA were scored quantitatively and comparatively across five dimensions： pharmacological characteristics， efficacy， safety， cost-effectiveness， and other attributes. RESULTS The comprehensive scores of the 12 formulations ranged from 62.56 to 75.50 points， with most scoring ≥70 points. Using the highest-scoring formulation for each generic name as a representative， the overall rankings of the five TPO-RA were as follows： Lusutrombopag tablets （75.50 points）， Eltrombopag olamine tablets （75.10 points）， Avatrombopag maleate tablets （70.40 points）， Romiplostim for injection （63.93 points）， and Herombopag olamine tablets （63.52 points）. Lusutrombopag tablets scored relatively high in pharmacological characteristics， safety， and cost-effectiveness， while Eltrombopag olamine tablets performed well in efficacy and cost-effectiveness. The other formulations showed varying scores across evaluation dimensions. CONCLUSIONS The five TPO-RA demonstrate favorable overall clinical value， with Lusutrombopag tablets and Eltrombopag olamine tablets ranking higher in comprehensive scores， these two drugs should be prioritized in drug selection and formula optimization by medical institutions.
